Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Explored as a possible aid for recovery and lean-mass preservation in frail or catabolic populations, though a Merck-sponsored Phase 2b trial in elderly hip-fracture patients (Adunsky et al., 2011, Archives of Gerontology and Geriatrics, PMID 21067829) was halted early over a cardiac safety signal rather than demonstrating a clear functional benefit
Representative Standard Curve Reportable range: 15.6 - 2000 pg/mL
FOXO4-DRI Quick Start FOXO4-DRI is a lab-made peptide studied as a senolytic a compound meant to clear out senescent cells
Critically, these effects were achieved without food intake suppression, distinguishing MOTS-c from GLP-1 receptor agonists whose primary mechanism involves appetite reduction
US$ 24.76
US$ 23.57
US$ 20.47
US$ 29.47
